Durvalumab impacts progression-free survival while high-dose radiation & gt;66  Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)

CONCLUSION: While Durvalumab impacts PFS, LC can be improved by total radiation doses > 66 Gy without excess toxicity.PMID:38653380 | DOI:10.1016/j.radonc.2024.110294

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 23, 2024 Category: Radiology Authors: Franz Zehentmayr Petra Feurstein Elvis Ruznic Brigitte Langer Brane Grambozov Marisa Klebermass Herbert H üpfel Johann Feichtinger Danijela Minasch Martin Heilmann Barbara Breitfelder Claudia Steffal Gisela Gastinger-Grass Karoline Kirchhammer Margit Kaz Source Type: research